All In Biotech

NDA 016295 · Waylis Therap

Droxia

Hydroxyurea · Oral · Antimetabolite

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jun 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1967

Dec 7, 1967

Approved uses

3

Original approval plus efficacy supplements

Registered trials

283

72 Phase 3, 37 recruiting

FAERS reports

21,038

15,821 serious, 3,183 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 26, 2026.

HYDREA is indicated for the treatment of: • Resistant chronic myeloid leukemia. • Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation. HYDREA is an antimetabolite indicated for the treatment of: Resistant chronic myeloid leukemia. (1) Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation. (1)

Mechanism: The precise mechanism by which hydroxyurea produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in tissue culture in rats and humans lend support to the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. This hypothesis explains why, under certain conditions, hydroxyurea may induce teratogenic effects. Three mechanisms of action have been postulated for the increased effectiveness of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 2003 Supplement 36 · Efficacy LetterLabelReview
  • Feb 25, 1998 Supplement 29 · Efficacy · priority review
  • Dec 7, 1967 Original approval · Type 1 - New Molecular Entity · priority review
4 products under this application
  • DROXIA · HYDROXYUREA 300MG · CAPSULE, ORAL · Prescription
  • HYDREA · HYDROXYUREA 500MG · CAPSULE, ORAL · Prescription · TE AB
  • DROXIA · HYDROXYUREA 400MG · CAPSULE, ORAL · Prescription
  • DROXIA · HYDROXYUREA 200MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydroxyurea" as an intervention, any sponsor and status, largest first.

All 283 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,223
  • fatigue1,546
  • sickle cell anaemia with crisis1,427
  • diarrhoea1,406
  • nausea1,312
  • headache1,066
  • anaemia1,055
  • death1,054
  • haemoglobin decreased941
  • pyrexia930
  • drug ineffective922
  • pain854

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004181
2005187
2006254
2007256
2008264
2009284
2010357
2011464
2012590
2013407
2014702
2015860
20161,216
20171,353
20181,675
20191,454
20201,718
20211,850
20221,900
20231,661
20241,326
20251,234
2026839

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Droxia (Hydroxyurea)

2024 spending

$165K

Beneficiaries

806

3,444 claims

Per beneficiary

$205

$0.75 per unit

View as table
YearSpending
2020$218,482
2021$236,270
2022$249,543
2023$173,563
2024$165,327

Part D: Hydrea (Hydroxyurea)

2024 spending

$39K

Beneficiaries

88

365 claims

Per beneficiary

$440

$1.25 per unit

View as table
YearSpending
2020$79,714
2021$67,181
2022$55,333
2023$40,412
2024$38,718

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 902 on PubMed

Sponsor: Waylis Therap · Also marketed as Hydrea

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.